Shares of TransMedics Group, Inc. (TMDX) surged 9.33% in after-hours trading on Thursday following the release of its impressive first-quarter 2025 financial results. The medical technology company, which focuses on organ transplant solutions, significantly outperformed analysts' expectations across multiple financial metrics.
TransMedics reported quarterly earnings of $0.70 per share, demolishing the analyst consensus estimate of $0.25 by a staggering 180%. This represents a 100% increase from the same period last year when the company earned $0.35 per share. Revenue for the quarter came in at $143.54 million, beating the analyst estimate of $123.66 million by 16.07% and marking a 48.21% year-over-year increase.
The company's profitability also showed remarkable improvement. TransMedics reported an income from operations of $27.443 million, more than doubling the IBES estimate of $10.1 million. The gross profit stood at $88.228 million with a robust gross margin of 61%. Additionally, the company provided an optimistic full-year revenue outlook of $565-585 million, further fueling investor enthusiasm. These strong results and positive outlook appear to be the primary drivers behind the stock's significant after-hours rally.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.